Results 71 to 80 of about 15,380 (223)

Dynamic changes during the treatment of pancreatic cancer [PDF]

, 2018
This manuscript follows a single patient with pancreatic adenocarcinoma for a five year period, detailing the clinical record, pathology, the dynamic evolution of molecular and cellular alterations as well as the responses to treatments with ...
et al,, Wang-Gillam, Andrea, Wolff, Robert A   +2 more
core   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX

BMJ Case Reports, 2018
The report describes a patient who presented to our centre with abdominal pain and significant weight loss due to adenocarcinoma of the tail of the pancreas. The cancer was deemed as ‘resectable disease associated with morbid surgical outcomes’ due to the local involvement of the vessels and adjacent organs.
Chien-Ting Kao, Muhammad Aziz, Anup Kasi
openaire   +3 more sources

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer

Cell Communication and Signaling
Background Pancreatic ductal adenocarcinoma (PDAC) remains a clinically challenging cancer, mainly due to limited therapeutic options and the presence of a highly prominent tumor microenvironment (TME), facilitating tumor progression.
Zainab Hussain, Thomas Bertran, Pascal Finetti, Eugenie Lohmann, Emilie Mamessier, Ghislain Bidaut, François Bertucci, Moacyr Rego, Richard Tomasini   +8 more
doaj   +1 more source

Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite‐unstable gastrointestinal cancers: A pilot study

International Journal of Cancer, Volume 158, Issue 12, Page 3312-3323, 15 June 2026.
What's new? A substantial proportion of patients with microsatellite‐unstable gastrointestinal adenocarcinomas do not benefit from immunotherapy. This study demonstrates that microsatellite instability can be reliably detected in plasma‐derived extracellular vesicle DNA from patients with microsatellite‐unstable gastrointestinal cancers.
Aysel Ahadova, Lena Bohaumilitzky, Thomas Walle, Joscha A. Kraske, Mirjam Tariverdian, Ulrike Ganserer‐Schmitt, Ingrid Hausser‐Siller, Vera Fuchs, Nina Nelius, Gizem Mehtap Erisen, Johannes Gebert, Albrecht Stenzinger, Dirk Jäger, Magnus von Knebel Doeberitz, Georg Martin Haag, Elena Busch, Matthias Kloor   +16 more
wiley   +1 more source

Comparative survival outcomes of surgical resection versus radiotherapy after FOLFIRINOX in borderline resectable and locally advanced pancreatic cancer [PDF]

Precision and Future Medicine
Purpose This study evaluated the clinical outcomes and prognostic factors in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) treated with upfront FOLFIRINOX followed by local-regional therapy ...
Jiwon Yu, Jeong Ha Lee, Hyunju Shin, Hee Chul Park, Joon Oh Park, Jung Yong Hong, Minsuk Kwon, Ji Eun Shin, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Young Hoon Choi, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Hongbeom Kim, Ji Hye Min, Jeong Il Yu   +18 more
doaj   +1 more source

A totally laparoscopic associating liver partition and portal vein ligation for staged hepatectomy assisted with radiofrequency (radiofrequency assisted liver partition with portal vein ligation) for staged liver resection [PDF]

, 2016
In order to induce liver hypertrophy to enable liver resection in patients with a small future liver remnant, various methods have been proposed in addition to portal vein embolisation.
Fajardo, A, Fang, R, Gall, TMH, Hakim, DN, Jiao, LR, Pencavel, T, Sordgren, MH   +6 more
core   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy

Clinical and Translational Radiation Oncology
Background: To evaluate the efficacy and optimal timing of local treatment in patients with borderline resectable (BR) or locally advanced pancreatic cancer (LAPC) treated with upfront FOLFIRINOX.
Kangpyo Kim, Hee Chul Park, Jeong Il Yu, Joon Oh Park, Jung Yong Hong, Kyu Taek Lee, Kwang Hyuck Lee, Jong Kyun Lee, Joo Kyung Park, Jin Seok Heo, Sang Hyun Shin, Ji Hye Min, Kyunga Kim, In Woong Han   +13 more
doaj   +1 more source